AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib showed favorable antitumor activity and an acceptable safety profile in treatment-naïve patients with PD-L1 TPS ≥ 1% NSCLC [195]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.